The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy
Sponsored by Assiut University
About this trial
Last updated 5 years ago
Study ID
Aromatase inhibitor in ectopic
Status
Unknown status
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18 to 40 Years
Female
Not accepting
Healthy Volunteers
Trial Timing
Ended 3 years ago
What is this trial about?
The aim of this study is to :
1. Use of the aromatase inhibitor( letrozole) for the treatment of ectopic pregnancy
compared to methotrexate.
2. Use of the Gnrh antagonist for the treatment of ectopic pregnancy compared to
methotrexate.
What are the participation requirements?
Inclusion Criteria
- Patients who have undisturbed ectopic pregnancy .Who are:
1. have no significant pain
2. have an unruptured tubal ectopic pregnancy with an adnexal mass smaller than 35mm with no visible heartbeat
3. have a serum human chorionic gonadotropins level less than 1,500 IU/litre
4. do not have an intrauterine pregnancy (as confirmed on an ultrasound scan) .
Exclusion Criteria
1. An undisturbed ectopic pregnancy and significant pain
2. An undisturbed ectopic pregnancy with an adnexal mass of 35 mm or larger
3. An undisturbed ectopic pregnancy with a fetal heartbeat visible on an ultrasound scan
4. An undisturbed ectopic pregnancy and a serum human chorionic gonadotropins level of 5,000 IU/litre or more
5. intrauterine pregnancy